– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor– On track for mid-2022 full enrollment of HopES trial for SM-88 u.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Tyme Technologies (NASDAQ:TYME) were jumping 19.5% as of 11:45 a.m. EST on Tuesday. The solid gain came after the biotech announced the close of a public stock offering of 40 million shares.
So what
It s typical for biotechs to sink after announcing stock offerings. And that s exactly what happened with Tyme Technologies stock last week. These declines make sense because the value of existing shares is diluted when more shares are issued.